Quest Journals Journal of Medical and Dental Science Research Volume 8~ Issue 7 (2021) pp: 13-16 ISSN(Online) : 2394-076X ISSN (Print):2394-0751 www.questjournals.org *Corresponding Author: R. Ghosh 13 | Page Research Paper Post-Covid Mucormycosis With Management: A Case Study R. Ghosh 1* , Dr. D. Ghosh 2 1 MBBS(FINAL), GSL Medical college and general hospital, Rajahmundry, Andhra Pradesh 2 MD(AY), Ph.D. (C.U), Superintendent and Ex-officio professor, Viswanath Ayurved Mahavidyalaya & Hospital, Kolkata , *corresponding author: R. Ghosh Received 20 June, 2021; Revised: 03 July, 2021; Accepted 05 July, 2021 © The author(s) 2021. Published with open access at www.questjournals.org I. INTRODUCTION: Mucormycosis is a rapidly progressive lethal form of fungal infection, formally known as Zygomycosis. This is an angioinvasive fungal infection caused by Mucorales fungus. This infection tends to occur most often who has weakened immunity from an illness or poor health condition. It is classified as rhinocerebral, pulmonary, cutaneous, gastrointestinal, disseminated, or other depending on the clinical presentation which includes unusual types such as endocarditis, osteomyelitis, peritonitis, renal, and so on. The condition was initially documented in 1876 by Fürbinger in Germany, who described a patient who died of cancer and had a hemorrhagic infarct in the right lung with fungal hyphae and a few sporangia. Arnold Paltauf described the first case of disseminated mucormycosis in 1885, calling it "Mycosis mucorina". (11)(9). The presence of sporangiophores and rhizoid-like structures in his illustrations of the etiologic agent led to the conclusion that the infection was most likely caused by Lichtheimia corymbifera. More instances have been diagnosed throughout time, and the disease's incidence has risen 12) (13) After Aspergillus, Mucorales fungi are the next most frequent mould pathogens, causing invasive fungal illness in individuals with cancer or transplant recipients. Mucormycosis has also become more common in persons with diabetes, which is the most frequent underlying risk factor worldwide. However, doctors are now noticing a rise in mucormycosis amongst the people hospitalized for or recovering from COVID-19. (10)(11) II. MUCORMYCOSIS AND COVID-19: The correlation between COVID-19 and Mucormycosis can be due to diabetes mellitus which is also a high-risk factor for COVID-19. Secondly, steroids that suppress immunity are the only treatment that decreases COVID-19 mortality. (7)(8)(9) So it is the combination of COVID-19, with decreased immunity and the steroids which probably predisposing factor to have the infection of Mucormycosis. A perfect environment of low oxygen (hypoxia), high glucose in the blood (steroid-induced hyperglycemia), acidic medium (metabolic acidosis, diabetic ketoacidosis [DKA]), high iron levels (increased ferritins), and decreased phagocytic activity of white blood cells appears to be facilitating Mucorales spores to germinate in people with COVID-19 due to immunosuppressed condition (SARS-CoV-2 mediated, steroid-mediated or some comorbidities) coupled with several other shared risk factors including prolonged hospitalization with or without mechanical ventilators. (1) III. A CASE OF MUCORMYCOSIS: POST COVID COMPLICATION: Case History: A 45 years male patient with moderate diabetes, had taken treatment for COVID 19 after his RT-PCR report was positive. He came to our hospital with a high fever, dyspnea, sore throat, headache, diarrhea. He had taken medicines from the physician of our hospital. On admission (21 March 2021, around 8 pm), He has prescribed the following medicines: (Treatment of Covid - 19): 1. Azithromycin 500 mg 1-0-0 2. Cefixime 200 mg 1-0-1 3. T. Dexamethasone 6 mg 1-0-0 4. T. Acetaminophen 650 mg SO 5. T. Vitamin C 500 mg 1-0-1 6. T. Pantoprazole 40 mg 1-0-0 7. C. Becosule – Z (Vitamin B Complex+ zinc) 1-0-0